An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion.

[1]  K. Huber,et al.  High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. , 2002, American heart journal.

[2]  Ren-Ke Li,et al.  A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis , 2002, Circulation.

[3]  D. Webb,et al.  Impaired Coronary Tissue Plasminogen Activator Release Is Associated With Coronary Atherosclerosis and Cigarette Smoking: Direct Link Between Endothelial Dysfunction and Atherothrombosis , 2001, Circulation.

[4]  M. Pfeffer,et al.  Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. , 2000, Circulation.

[5]  D. Newby,et al.  Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men. , 2003, Journal of the American College of Cardiology.

[6]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[7]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[8]  G. Breithardt,et al.  Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[9]  I. Macgregor,et al.  Venous Occlusion Does Not Release von Willebrand Factor, Factor VIII or PAI-1 from Endothelial Cells – The Importance of Consensus on the Use of Correction Factors for Haemoconcentration , 1993, Thrombosis and Haemostasis.

[10]  S. Rahimtoola,et al.  Impaired fibrinolysis in coronary artery disease. , 1988, American heart journal.

[11]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[12]  W. Fiers,et al.  Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Devaraj,et al.  C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells: Implications for the Metabolic Syndrome and Atherothrombosis , 2003, Circulation.

[14]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[15]  P. Ridker,et al.  Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men , 1998, The Lancet.

[16]  P. Ridker.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.

[17]  K. Huber,et al.  Impairment of the Plasmin Activation System in Primary Pulmonary Hypertension: Evidence for Gender Differences , 2001, Thrombosis and Haemostasis.

[18]  I. Nilsson,et al.  “FIBRINOLYTIC CAPACITY” IN HEALTHY VOLUNTEERS AT DIFFERENT AGES AS STUDIED BY STANDARDIZED VENOUS OCCLUSION OF ARMS AND LEGS , 1972, Acta medica Scandinavica.

[19]  M. Gimbrone,et al.  Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. , 1988, The Journal of biological chemistry.

[20]  S. Devaraj,et al.  C-Reactive Protein Decreases Prostacyclin Release From Human Aortic Endothelial Cells , 2003, Circulation.